glp-1 agonist benefits Drugs & What They Do Part 3 of a 3-Part

At MNT , we dedicated a podcast episode to this

Racial and ethnic disparities are evident, with Asian, Black, and Hispanic patients less likely to receive these medications compared to White patients, partly due to structural racism and socioeconomic factors

GLP-1s dont have the same effectiveness on everyone, but to date we dont yet know what will make you a better responder to the treatment, but its effective very broadly

Second, T2DM patients who received various GLP-1 receptor agonist drugs, such as albiglutide, exenatide, liraglutide, semaglutide, lixisenatide and dulaglutide might have biased the meta-analysis results

The other phase IIa study also confirmed improved glycemic control in those with obesity and T2DM, but also reported decreased body weight and improvement of blood lipids compared to placebo [44]

Patients interested in the program should consult their healthcare provider to begin the screening and prior authorization process well in advance of the July launch date.